Alembic Pharma arm inks pact with Curon to develop cancer treatment drug in Greater China

As per the agreement, Rhizen will receive an undisclosed upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of USD 149.5 million plus double-digit royalties.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3dkyW9Y
via IFTTT